High neutrophil-to-lymphocyte ratio is associated with relapse in Graves’ disease after antithyroid drug therapy
Antithyroid drugs (ATDs) are effective in controlling hyperthyroidism due to Graves’ disease (GD); however, long-term remission rates are low. The neutrophil-to-lymphocyte ratio (NLR) is a useful prognostic marker in many inflammatory diseases. We aimed to evaluate whether NLR can be used as a prognostic marker for relapse in patients with GD after ATD therapy.
This retrospective cohort study included 108 patients with newly diagnosed GD who achieved remission after ATD therapy and were followed-up for >12 months after ATD discontinuation. The primary outcome was relapse-free survival (RFS).
Patients were classified into two groups according to baseline NLR: low NLR group with NLR < 1.14 (n = 59; 55%) and high NLR group with NLR ≥ 1.14 (n = 49; 45%). During the median follow-up of 6.5 years, disease relapse after a year of ATD withdrawal occurred in 23 (21%) patients. The patients with high NLR had poorer RFS than those with low NLR, and RFS curves were significantly different between the two groups (p = 0.002). In multivariate analysis, a high NLR (OR = 4.22, p = 0.016) was an independent prognostic factor for relapse in patients with GD after adjusting for age, sex, goiter, orbitopathy, thyroid hormone levels, thyrotropin binding inhibiting immunoglobulin titer, and the duration of ATD therapy.
This study showed that NLR can be an early and cost-effective prognostic biomarker for relapse in patients with GD after ATD therapy. Further studies are needed to validate the prognostic role of NLR in GD.
KeywordsNeutrophil Lymphocyte Graves’ disease Antithyroid drug Relapse
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study protocol was approved by the institutional review board of PNUH, Busan, the Republic of Korea (No. 1906-013-080).
- 1.D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia, S.A. Rivkees, M. Samuels, J.A. Sosa, M.N. Stan, M.A. Walter, 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 26(10), 1343–1421 (2016). https://doi.org/10.1089/thy.2016.0229 CrossRefPubMedPubMedCentralGoogle Scholar
- 2.W.G. Kim, W.B. Kim, G. Woo, H. Kim, Y. Cho, T.Y. Kim, S.W. Kim, M.H. Shin, J.W. Park, H.L. Park, K. Oh, J.H. Chung, Thyroid stimulating hormone reference range and prevalence of thyroid dysfunction in the Korean population: Korea National Health and Nutrition Examination Survey 2013 to 2015. Endocrinol. Metab. 32(1), 106–114 (2017). https://doi.org/10.3803/EnM.2017.32.1.106 CrossRefGoogle Scholar
- 5.P. Abraham, A. Avenell, S.C. McGeoch, L.F. Clark, J.S. Bevan, Antithyroid drug regimen for treating Graves’ hyperthyroidism. The Cochrane database of systematic reviews (1), Cd003420 (2010). https://doi.org/10.1002/14651858.CD003420.pub4
- 6.P. Anagnostis, F. Adamidou, S.A. Polyzos, S. Katergari, E. Karathanasi, C. Zouli, A. Panagiotou, M. Kita, Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine 44(2), 448–453 (2013). https://doi.org/10.1007/s12020-013-9895-0 CrossRefPubMedGoogle Scholar
- 8.S. Park, E. Song, H.S. Oh, M. Kim, M.J. Jeon, W.G. Kim, T.Y. Kim, Y.K. Shong, D.M. Kim, W.B. Kim, When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves’ disease be discontinued? Endocrine 65(2), 348–356 (2019). https://doi.org/10.1007/s12020-019-01987-w CrossRefPubMedGoogle Scholar
- 9.S. Chittawar, D. Dutta, Z. Qureshi, V. Surana, S. Khandare, T.N. Dubey, Neutrophil-lymphocyte ratio is a novel reliable predictor of nephropathy, retinopathy, and coronary artery disease in Indians with type-2 diabetes. Indian J. Endocrinol. Metab. 21(6), 864–870 (2017). https://doi.org/10.4103/ijem.IJEM_197_17 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.A.J. Templeton, M.G. McNamara, B. Seruga, F.E. Vera-Badillo, P. Aneja, A. Ocana, R. Leibowitz-Amit, G. Sonpavde, J.J. Knox, B. Tran, I.F. Tannock, E. Amir, Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl Cancer Inst. 106(6), dju124 (2014). https://doi.org/10.1093/jnci/dju124 CrossRefPubMedGoogle Scholar
- 11.A. Kucuk, A.U. Uslu, Y. Ugan, S. Bagcaci, A.Y. Karahan, A. Akarmut, A. Sahin, S. Kucuksen, Neutrophil-to-lymphocyte ratio is involved in the severity of ankylosing spondylitis. Bratisl. Lekarske Listy 116(12), 722–725 (2015)Google Scholar
- 13.I. Kocyigit, E. Eroglu, A. Unal, M.H. Sipahioglu, B. Tokgoz, O. Oymak, C. Utas, Role of neutrophil/lymphocyte ratio in prediction of disease progression in patients with stage-4 chronic kidney disease. J. Nephrol. 26(2), 358–365 (2013). https://doi.org/10.5301/jn.5000152 CrossRefPubMedGoogle Scholar
- 14.B. Biondi, L. Bartalena, D.S. Cooper, L. Hegedus, P. Laurberg, G.J. Kahaly, The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur. thyroid J. 4(3), 149–163 (2015). https://doi.org/10.1159/000438750 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.World Health Organization. Assessment of iodine deficiency disorders and monitoring their elimination: a guide for programme managers, 3rd ed. (2007).Google Scholar
- 16.L. Bartalena, L. Baldeschi, A.J. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M.P. Mourits, P. Perros, K. Boboridis, A. Boschi, N. Curro, C. Daumerie, G.J. Kahaly, G. Krassas, C.M. Lane, J.H. Lazarus, M. Marino, M. Nardi, C. Neoh, J. Orgiazzi, S. Pearce, A. Pinchera, S. Pitz, M. Salvi, P. Sivelli, M. Stahl, G. von Arx, W.M. Wiersinga, Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 18(3), 333–346 (2008). https://doi.org/10.1089/thy.2007.0315 CrossRefPubMedGoogle Scholar
- 17.F. Lee, P.S. Yang, M.N. Chien, J.J. Lee, C.H. Leung, S.P. Cheng, An increased neutrophil-to-lymphocyte ratio predicts incomplete response to therapy in differentiated thyroid cancer. Int. J. Med. Sci. 15(14), 1757–1763 (2018). https://doi.org/10.7150/ijms.28498 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.R. Zahorec, Ratio of neutrophil to lymphocyte counts–rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl. Lekarske Listy 102(1), 5–14 (2001)Google Scholar
- 21.M. Dağdeviren, T. Akkan, D. Yapar, S. Karakaya, T. Dağdeviren, D. Ertuğrul, M. Altay, Can neutrophil/lymphocyte ratio be used as an indicator of inflammation in patients with hyperthyroidism? (2019). https://doi.org/10.2478/jomb-2019-0004
- 24.K. Van der Weerd, P.M. Van Hagen, B. Schrijver, D.J. Kwekkeboom, W.W. De Herder, M.R. Ten Broek, P.T. Postema, J.J. Van Dongen, F.J. Staal, W.A. Dik, The peripheral blood compartment in patients with Graves’ disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes. Clin. Exp. Immunol. 174(2), 256–264 (2013). https://doi.org/10.1111/cei.12183 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.B.G. Nedrebo, P.I. Holm, S. Uhlving, J.I. Sorheim, S. Skeie, G.E. Eide, E.S. Husebye, E.A. Lien, S. Aanderud, Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur. J. Endocrinol. 147(5), 583–589 (2002)CrossRefGoogle Scholar
- 34.A.K. Eckstein, H. Lax, C. Losch, D. Glowacka, M. Plicht, K. Mann, J. Esser, N.G. Morgenthaler, Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin. Endocrinol. 67(4), 607–612 (2007). https://doi.org/10.1111/j.1365-2265.2007.02933.x CrossRefGoogle Scholar